medigraphic.com

2009, Número 1

<< Anterior Siguiente >>

Anales de Radiología México 2009; 8 (1)


Adenocarcinoma de páncreas

Perez JR, Sahani D

Idioma: Español
Referencias bibliográficas: 46
Paginas: 21-31
Archivo PDF: 1865.38 Kb.


RESUMEN

Introducción: El adenocarcinoma de páncreas es una de las principales causas de muerte por cáncer, con una sobrevida pobre a cinco años de aproximadamente 4%. Su presentación clínica tardía, y su diagnóstico en estadio avanzado resultan en una baja proporción de intervenciones quirúrgicas.
Abordaje de tratamiento: El abordaje del tratamiento se basa en la posibilidad de resecar el tumor. Por lo tanto el papel de la Radiología es crucial, ya que permite estadificar al paciente y determinar su tratamiento. Diversas modalidades de imagen están disponibles para caracterizar una lesión pancreática como la Tomografía Computarizada con medio de contraste, la Resonancia Magnética y la Tomografía por Emisión de Positrones con Tomografía Computarizada Integrada. Dentro de los métodos de imagen invasivos se encuentran la colangiopancreatografia retrógrada endoscópica y el ultrasonido endoscópico. Cada modalidad tiene sus ventajas y sus debilidades.
Conclusión: La MDCT contrastada actualmente es la imagen principal para la detección y estadificación del carcinoma de páncreas. El híbrido PET/CT combina los beneficios estructurales de la tomografía y funcional del PET, ajustando el protocolo de adquisición de la tomografía para obtener fases vasculares adecuadas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Cancer Facts and Figures 2008. American Cancer Society, 2008.

  2. Compendio de Cancer. RHNM 2001. México: Registro Histopatológico de Neoplasias Malignas.

  3. Freeny PC, Traverso LW, Ryan JA. Diagnosis and staging of pancreatic adenocarcinoma with dynamic computed tomography. Am J Surg 1993; 165: 600-6.

  4. Poston GJ, Williamson RC. Causes, diagnosis, and management of exocrine pancreatic cancer. Compr Ther 1990; 16: 36-42.

  5. Tsuchiya R, Noda T, Harada N, et al. Collective review of small carcinomas of the pancreas. Ann Surg 1986; 203: 77-81.

  6. De Witt J, Devereaux B, Chriswell M, et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med 2004; 141: 753-63.

  7. Katz M, Pisters P, Evans D, et al. Borderline Resectable Panceratic Cancer: The importance of this emerging Stage of Disease. J Am Coll Surg 2007; 206(5): 833-46.

  8. Sahani S, Shah Z, Catalano O, Boland G, Brugge W. Radiology of pancreatic adenocarcinoma: current status of imaging. J Gastroenterol Hepatol 2008; 23: 23-33.

  9. Gangi S, Fletcher JG, Nathan MA et al. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. AJJR Am J Roentgenol 2004; 82: 897-903.

  10. Vargas R, Nino-Murcia M, Trueblood W, et al. MDCT in pancreatic adenocarcinoma: prediction of vascular invasion and respectability using multiphasic technique with curved planar reformations. AJR Am J Roentgenol 2004; 182: 419-25.

  11. O’ Malley ME, Boland GW, Wood BJ, et al. Adenocarcinoma of the head of the pancreas: determination of surgical unresectability with thin-section pancreaticphase helical CT. AJR Am J Roentgenol 1999; 173: 1513-18.

  12. Fletcher JG, Wiersema MJ, Farrell MS, et al. Pancreatic malignancy value of arterial, pancreatic, and hepatic phase imaging with multidetector row CT. Radiology 2003; 229: 81-90.

  13. Fletcher JG, Wiersema MJ, Farrell MA. Pancreatic malignancy: value of arterial, pancreatic, and hepatic phase imaging with multi-detector row CT. Radiology 2003; 229: 81-90.

  14. Tublin M, Tessler F, Cheng SL. Effect of injection rate of contrast medium on pacnreatic and hepatic helical CT. Radiology 1999; 210: 97-101.

  15. Legmann P, Vignaux o, Dousset B, et al. Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol 1998; 170: 1315-22.

  16. Baum U, Lell M, Nomayr A et al. Multiplanar spiral CT in the diagnosis of pancreatic tumors. Radiology 1999; 39: 958-64.

  17. Prokesh RW, Chow LC, Beaulieu CT, et al. Isoattenuating pancreatic adenocarcinoma at multidetector row CT: secondary signs. Radiology 2002; 224: 764-8.

  18. Zamboni G, Kruskal J, Vollmer C, Baptista J et al. Pancreatic adenocarcinoma. Value of multidetector CT angiography in the preoperative Evaluation. Radiology 2007; 245(3): 770-8.

  19. Fishman EK, Horton KM, Urban BA. Multidetector CT angiography in the evaluation of pancreatic carcinoma: preliminary observations. J Comput Assisst Tomogr 2000; 24: 849-53.

  20. Mertz H, Sechopoulos P, Delbeke D, et al. EUS, PET and CT scanning for the evaluation of pancreatic adenocarcinomas. Gastrointest Endosc 200; 52: 367-71.

  21. Bipat S, Phoa SS, van Delden OM et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining respectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr 2005; 29: 438-45.

  22. Martin DR, Semelka RC. MR imaging of pancreatic masses. Magn Reson Imaging Clin N Am 2000; 8: 787-812.

  23. Freeny PC. Pancreatic imaging: new modalities. Gastroenterol Clin N Am 1999; 28: 723-46.

  24. Fukukura Y, Fujiyoshi F, Sasaki M, et al. Pancreatic duct: morphologic evaluation with dynamic MR cholangiopancreatography after secretin stimulation. Radiology 2002; 222: 674-80.

  25. Matos C, Metens T, Deviere J et al. Pancreatic duct: morphological and functional evaluation with dynamic MR pancreatography after secretin stimulation. Radiology 1997; 203: 435-41.

  26. Manfredi R, Costamagna G, Brizi MG et al. Severe chronic pancreatitis versus suspected pancreatic disease: dynamic MR cholangiopancreatography after secretin stimulation. Radiology 2000; 214: 849-55.

  27. Hellerhoff KL, Helmberger H, Rosch T et al. Dynamic MR pancreatography after secretin administration: image quality and diagnostic accuracy. AJR Am J Roentgenol 2002; 179: 121-9.

  28. Flier JS, Mueckler MM, Usher P, et al. Elevated levels of glucose transport and transporter messenger RNA are induced by rats or src oncogenes. Science 1987; 235: 1492-5.

  29. Higashi T, Tamaki N, Honda T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased F-18 FDG accumulation in PET study. J Nucl Med 1997; 38: 1337-44.

  30. Reske S, Grillenberger KG, Glatting G, et al. Overexpression of glucose transporter 1 and increased F-18 FDG uptake in pancreatic carcinoma. J Nucl Med 1997; 38: 1344-8.

  31. Heinrich S, Goerres GW, Shafer M, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005; 235-45.

  32. Rosch T, Lorenz R, Braig C, et al. Endoscopic ultrasound in pancreatic tumor diagnosis. Gastrointest Endosc 1991; 37: 347-52.

  33. Brugge WR, Lee MJ, Kelsey PB, et al. The use of EUS to diagnose malignant portal venous system invasion by pancreatic cancer. Gastrointest Endosc 1996; 43: 561-7.

  34. Aslanian H, Salem R, Lee J, et al. EUS diagnosis of vascular invasion in pancreatic cancer: surgical and histological correlates. Am J Gastroenterol 2005; 100: 1381-5.

  35. Kim JK, HA, HK, Han DJ. CT analysis of postoperative tumor recurrence patterns in periampullary cancer. Abdom Imaging 2003; 28: 384-91.

  36. Ruf J, Lopez Hanninen E, Oettle H, et al. Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 2005; 5(2-3): 266-72.

  37. Rose DM, Delbeke D, Beauchamp RD, et al. 18Fluorodeoxyglucose- positron emission tomography (18FDG - PET) in the management of patients with suspected pancreatic cancer. Ann Surg 1998; 229: 729-38.

  38. de Vos tot Nederveen Cappel WH, Lagendijk MA, Lamers CB et al. Surveillance for familiar pancreatic cancer. Scand J Gastroenterol 2003; 239: S94-S99.

  39. Rieder H, Bartsch DK. Familial pancreatic cancer. Fam Cancer 2004; 3: 69-74.

  40. Canto Mi, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004; 2: 606-21.

  41. Berman JJ, Albores-Saavedra J, Bostwick D et al. Precancer: A conceptual working definition. Results of a consensos conference. Cancer Dtect Prev 2006; 30(5): 387-94.

  42. Hruban, Maitra A, Kern SE, Goggins M. Gastroenterol Clin N Am 2007; 36: 831-49.

  43. Hruban RH, Pitman MB, Klimstra DS. Tumors of the páncreas. Atlas of pathology. Fourth Series. Fascicle 6th. Ed. Washington D.C.: American Registry of Pathology and Armed Forces Institute of Pathology; 2007.

  44. Tanaka M, Chari S, Adsay V, Fernandezdel Castillo, et al. International Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and Mucinous Cystic Neoplasms of the páncreas. Pancreatology 2006; 6: 7-32.

  45. Lacobuzio-Donahue CA, Wilentz RE, Argani P, et al. Dpc4 proterin in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggest a role in genetic progression. Am J Surg Pathol 2000; 24(11): 1544-8.

  46. Brune KA, Abe T, Canto MI, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the páncreas in patients having a strong family history of pancreatic cancer. Am J of Surg Pathol 2006; 30(9): 1067-76.




2020     |     www.medigraphic.com